• Gemcitabine HCl: From Assay Signal to MRI

  2026-09-01

  Gemcitabine HCl research is most informative when molecular cytotoxicity measurements are interpreted alongside longitudinal tumor anatomy. This guide presents a decision-focused framework for connecting DNA replication inhibition, apoptosis assays, and multianimal MRI without treating any single endpoint as a complete measure of therapeutic response.

• SMC2 and SMC4 in Breast Cancer Prognosis

  2026-09-01

  The 2024 study integrated multi-database bioinformatics with cell and xenograft experiments to identify SMC2 and SMC4 as independent prognostic factors in breast cancer. Its drug-response findings further suggest that SMC2/SMC4 status may influence sensitivity to 5-Fluorouracil and oxaliplatin, although prospective and subtype-specific validation remains necessary.

• Cimetidine for BBB and Cancer Research Workflows

  2026-08-31

  Cimetidine can serve as a mechanistic H2R probe across barrier-transport and gastrointestinal cancer workflows without being mistaken for a validated BBB standard. This guide combines practical Transwell assay design, lysosomal-trapping controls, solubility handling, and interpretation strategies for more reproducible research.

• Talabostat Mesylate: Reframing FAP and DPP4 Biology

  2026-08-31

  Talabostat mesylate, also known as PT-100 or Val-boroPro, offers translational researchers a way to interrogate the intersection of DPP4 biology, FAP-positive stroma, immune signaling, and hematopoiesis. This article connects enzymatic mechanism with experimental strategy, biomarker development, and the practical limits of interpreting antitumor activity.

• Oligo (dT) 25 Beads: Practical mRNA Workflow

  2026-08-30

  Oligo (dT) 25 Beads provide a magnetic method for enriching polyadenylated eukaryotic mRNA from total RNA or eukaryotic cell and tissue samples. They are appropriate for mRNA-focused workflows such as RT-PCR and cDNA synthesis, but should not be treated as a universal method for non-polyadenylated RNA, prokaryotic RNA, or unbiased total-RNA recovery.

• SmD2 Acetylation Shapes PARP Response in HCC

  2026-08-29

  This 2024 Nature Communications study identifies acetylation-dependent control of the spliceosome protein SmD2 as a mechanistic link between alternative splicing, BRCA1/FANC expression, DNA damage repair, and PARP inhibitor sensitivity in hepatocellular carcinoma. Its preclinical data support SmD2 and the HDAC2–p300 regulatory axis as potential determinants of response, while combination treatment with Romidepsin and Olaparib provides a rationale for further investigation in BRCA-proficient HCC.

• Plk1 Control of p31comet in Mitotic Checkpoint Exit

  2026-08-28

  The reference study identifies Polo-like kinase 1 (Plk1) as a direct regulator of p31comet, showing that phosphorylation at S102 suppresses p31comet–TRIP13-mediated disassembly of mitotic checkpoint complexes. This mechanism helps explain how active checkpoint signaling avoids a futile cycle of MCC assembly and disassembly and provides a useful framework for studying mitotic exit control.

• Genomic Instability and Therapy Heterogeneity in CRC

  2026-08-28

  Cho et al. combine patient-derived xenografts with whole-exome, transcriptomic, and DNA-methylation profiling to show that colorectal cancer metastasis is accompanied by coordinated genomic and regulatory change. Their results connect metastatic evolution with heterogeneous treatment responses, providing a mechanistic framework for studying resistance beyond a static primary-tumor biopsy.

• U 46619: From TP Signaling to Translational Strategy

  2026-08-27

  U 46619, also known as 11,9 epoxymethano-prostaglandin H2, is a selective TP receptor agonist that connects platelet activation with vascular and renal research. This thought-leadership guide shows how to use its mechanism, concentration-dependent readouts, and translational limitations to design stronger platelet, vascular tone, and hypertension studies.

• Self-Amplifying RNA Influenza Vaccines: Key Findings

  2026-08-27

  A 2026 study found that self-amplifying RNA produced stronger and more durable protection against influenza B than conventional nucleoside-modified mRNA in mice, while preserving dose-sparing performance against influenza A. The work highlights influenza-subtype and platform-specific determinants of RNA vaccine immunogenicity and provides a useful framework for comparing RNA vaccine architectures.

• AmpliFold Capture-and-Release for LFA Sensitivity

  2026-08-26

  The AmpliFold strategy addresses a central limitation of lateral flow assays: insufficient time for efficient analyte capture at a narrow test line. In a HER2 model, triggered release from a broad capture region followed by high-affinity rebinding produced up to 16-fold sensitivity enhancement and improved detection of large nanoparticles in buffer and serum.

• DeferoxamineB as a Control for Cell-Death Assays

  2026-08-26

  DeferoxamineB is a powerful iron-dependent perturbation tool for cancer research. This guide explains how to use Deferoxamine to distinguish ferroptosis, apoptosis, autophagy, and cuproptosis while improving metabolic assay design and interpretation.

• Alternariol AOH: From Exposure to Assay Design

  2026-08-25

  Alternariol (AOH) is more than a foodborne mycotoxin model: it is a layered perturbation tool for connecting metabolism, cell death, cytoskeletal remodeling, and hepatic stellate-cell activation. This guide translates recent LX-2 findings into practical assay decisions, controls, and interpretation strategies.

• Stattic Workflows for STAT3-Driven Cancer Research

  2026-08-25

  Stattic is a practical STAT3 inhibitor for connecting pathway mechanism with measurable cancer phenotypes, from nuclear translocation and apoptosis to radiosensitization. This workflow-focused guide shows how to apply it in HNSCC models and cautiously test the NF-κB–IL6–STAT3 biology highlighted in prostate cancer microbiome research.

• Potassium Iodide: Thyroid & Assay Workflows

  2026-08-24

  Potassium Iodide provides a defined iodide source for thyroid uptake, hormone-synthesis, and radioactive iodine competition studies. This protocol-driven guide also explains how to use KI as a carefully controlled compatibility variable alongside responsive liposome research—without confusing an analytical reagent with an immunotherapy payload.

8115 records 1/541 page Next 12345 下5页 Last page